Disease patterns and causes of death of hospitalized HIV-positive adults in West Africa: A multicountry survey in the antiretroviral treatment era

Journal of the International AIDS Society

Volumn 17, Issue , 2014, Pages

  Lewden, Charlotte ^a,b   Drabo, Youssoufou J ^c   Zannou, Djimon M ^d   Maiga, Moussa Y ^e,i   Minta, Daouda K ^f,i   Sow, Papa S ^g   Akakpo, Jocelyn ^d   Dabis, François ^a,b   Eholié, Serge P ^h   Zannou, Djimon Marcel ⁱ   Koumakpaï, Sikiratou ⁱ   Drabo, Joseph ^j   Sawadogo, Adrien Bruno ^k   Yé, Diarra ⁱ   Messou, Eugène ⁱ   Bosse, Clarisse Amani ⁱ   Chenal, Henri ⁱ   Minga, Albert ⁱ   Eholié, Serge Paul ^l   Koule, Serge Olivier ^l   Aka, Edmond Addi ⁱ   Pety, Touré ⁱ   Kouakou, Kouadio ⁱ   Folquet, Madeleine Amorissani ^m   Eboua, Tanoh François ⁿ   Renner, Lorna ^o   Wejse, Christian ^p   Da Silva, Zacarias José ^p   Traore, Hamar Alassane ⁱ   Dicko, Fatoumata ⁱ   Charurat, Man ⁱ   Ajayi, Samuel ^q   Benson, Okwara ^r   Adebamowo, Clément ^r   Seydi, Moussa ^s   Sy, Haby Signate ⁱ   Patassi, Akessiwe ^t   Lawson Evi, Koko ^t   Gottlieb, Geoffrey S ⁱ   more..

^a UNIVERSITÉ DE BORDEAUX   (France)

^b INSERM   (France)

^c University Hospital Yalgado Ouedraogo   (Burkina Faso)

^d Universitaire Hubert Koutoukou Maga   (Benin)

^e HÔPITAL GABRIEL TOURÉ   (Mali)

^f Hopital National du Point G   (Mali)

^g Thoracic and Cardiovascular Surgery Clinic   (Senegal)

^h University Hospital of Treichville   (Côte d’Ivoire)

ⁱ CNHU Hubert Maga ^*

^j Service d'Urologie   (Burkina Faso)

^k CHU Souro Sanou   (Burkina Faso)

^l CENTRE HOSPITALIER UNIVERSITAIRE DE TREICHVILLE   (Côte d’Ivoire)

^m CHU de Cocody   (Côte d’Ivoire)

ⁿ CHU Yopougon   (Côte d’Ivoire)

^o KORLE BU TEACHING HOSPITAL   (Ghana)

^p BANDIM HEALTH PROJECT   (Guinea-Bissau)

^q UATH   (Nigeria)

^r UBTH   (Nigeria)

^s SMIT CHU Fann   (Senegal)

^t CHU Tokoin Sylvanus Olympio   (Côte d’Ivoire)

more..

Author keywords

Africa; AIDS; Antiretroviral therapy; HIV infection; Hospitalization; Morbidity

Indexed keywords

ANTIRETROVIRUS AGENT; CLINDAMYCIN; COTRIMOXAZOLE; FLUCONAZOLE; PYRIMETHAMINE; SULFADIAZINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AFRICA; AMEBIASIS; ANEMIA; ARTICLE; BACTERIAL PNEUMONIA; BLASTOCYSTOSIS; CAUSE OF DEATH; CD4 LYMPHOCYTE COUNT; CEREBRAL TOXOPLAMOSIS; CRYPTOCOCCOSIS; CRYPTOSPORIDIOSIS; CYTOMEGALOVIRUS INFECTION; DISEASE CLASSIFICATION; DISEASE COURSE; ENDOCARDITIS; ERYSIPELAS; ESOPHAGUS CANDIDIASIS; FEMALE; GIARDIASIS; HEALTH SURVEY; HEPATITIS B; HERPES SIMPLEX; HERPES ZOSTER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED DEMENTIA; HOSPITAL DISCHARGE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTIOUS DIARRHEA; ISOSPORIASIS; KAPOSI SARCOMA; LIVER CELL CARCINOMA; LUNG ABSCESS; MAJOR CLINICAL STUDY; MALARIA; MALE; MENINGITIS; MICROSPORIDIOSIS; MOLLUSCUM CONTAGIOSUM; MULTICENTER STUDY; MYOSITIS; NONHODGKIN LYMPHOMA; OSTEOMYELITIS; PNEUMOCYSTOSIS; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROSPECTIVE STUDY; PYELONEPHRITIS; SALPINGITIS; SCHISTOSOMIASIS; SEPSIS; SHIGELLOSIS; SINUSITIS; SKIN LEISHMANIASIS; STRONGYLOIDIASIS; TETANUS; THRUSH; TOXOPLASMOSIS; TUBERCULOSIS; URINARY TRACT INFECTION; UTERINE CERVIX CARCINOMA; VAGINA CANDIDIASIS;

AFRICA; AIDS; ANTIRETROVIRAL THERAPY; HIV INFECTION; HOSPITALIZATION; MORBIDITY;

ADULT; AFRICA, WESTERN; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; CAUSE OF DEATH; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED;

EID: 84899982290     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.7448/IAS.17.1.18797     Document Type: Article

References (54)

1. CASCADE Collaboration. Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet. 2003;362:1267-74.
2. The Antiretroviral Therapy in Lower Income Countries (ART-LINC) Collaboration, The Antiretroviral Therapy (ART) Cohort Collaboration. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet. 2006;367:817-24.
3. Laurent C, Diakhate N, Gueye NFN, Toure MA, Sow PS, Faye MA, et al. The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up study. AIDS. 2002;16:1363-70. (Pubitemid 34722068)
4. Seyler C, Messou E, Gabillard D, Inwoley A, Alioum A, Anglaret X. Morbidity before and after HAART initiation in Sub-Saharan African HIV-infected adults: a recurrent event analysis. AIDS Res Hum Retroviruses. 2007;23:1338-47.
5. UNAIDS. Global report. UNAIDS Report on the global AIDS epidemic 2013 [Internet]. 2013 [cited 2013 Nov 12]. Available from: http://www.unaids.org/en/ media/unaids/contentassets/documents/epidemiology/2013/gr2013/ UNAIDS-Global-Report-2013-en.pdf
6. UNAIDS. Global report. UNAIDS Report on the global AIDS epidemic [Internet]. 2012 [cited 2013 Feb 15]. Available from: http://www.unaids.org/en/ resources/campaigns/20121120-globalreport2012/globalreport/
7. Eholie SP, Aoussi FE, Ouattara IS, Bissagnene E, Anglaret X. HIV treatment and care in resource-constrained environments: challenges for the next decade. J Int AIDS Soc. 2012;15:17334.
8. Moh R, Danel C, Messou E, Ouassa T, Gabillard D, Anzian A, et al. Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa. AIDS. 2007;21:2483-91. (Pubitemid 350145180)
9. Etard JF, Ndiaye I, Thierry-Mieg M, Gueye NF, Gueye PM, Laniece I, et al. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS. 2006;20:1181-9. (Pubitemid 43786107)
10. Lawn SD, Myer L, Orrell C, Bekker LG, Wood R. Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS. 2005;19:2141-8. (Pubitemid 41669003)
11. Gabillard D, Lewden C, Ndoye I, Moh R, Segeral O, Tonwe-Gold B, et al. Mortality, AIDS-morbidity and loss to follow-up by current CD4 cell count among HIV-1 infected adults receiving antiretroviral therapy in Africa and Asia: data from the ANRS 12222 collaboration. J Acquir Immune Defic Syndr. 2013;62:555-61.
12. Lawn SD, Badri M, Wood R. Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort. AIDS. 2005;19:2109-16. (Pubitemid 41668999)
13. Curtis AJ, Marshall CS, Spelman T, Greig J, Elliot JH, Shanks L, et al. Incidence of WHO stage 3 and 4 conditions following initiation of anti-retroviral therapy in resource limited settings. PLoS One. 2012;7:e52019.
14. Beauliere A, Toure S, Alexandre PK, Kone K, Pouhe A, Kouadio B, et al. The financial burden of morbidity in HIV-infected adults on antiretroviral therapy in Cote d'Ivoire. PLoS One. 2010;5:e11213.
15. Boyer S, Marcellin F, Ongolo-Zogo P, Abega SC, Nantchouang R, Spire B, et al. Financial barriers to HIV treatment in Yaounde, Cameroon: first results of a national cross-sectional survey. Bull World Health Organ. 2009;87:279-87.
16. Boulle A, Orrel C, Kaplan R, Van Cutsem G, McNally M, Hilderbrand K, et al. Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort. Antivir Ther. 2007;12:753-60. (Pubitemid 47235489)
17. Lewden C, May T, Rosenthal E, Burty C, Bonnet F, Costagliola D, et al. Changes in causes of death among adults infected by the Human Immunodeficiency Virus (HIV) between 2000 and 2005. The "Mortalité 2000 & 2005" surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr. 2008; 48:590-8.
18. Teja VD, Sudha T, Lakshmi V. Causes and pattern of mortality in HIV-infected, hospitalized patients in a tertiary care hospital: a fourteen year study. Indian J Med Sci. 2007;61:555-61. (Pubitemid 47628607)
19. Kumar A, Kilaru KR, Sandiford S, Forde S. Profile of hospitalized HIV-infected persons in the highly active antiretroviral therapy era in Barbados. J Int Assoc Physicians AIDS Care (Chic Ill). 2007;6:101-5.
20. Saleri N, Capone S, Pietra V, De Iaco G, Del Punta V, Rizzi M, et al. Outcome and predictive factors of mortality in hospitalized HIV-patients in Burkina Faso. Infection. 2009;37:142-7.
21. Agaba PA, Digin E, Makai R, Apena L, Agbaji OO, Idoko JA, et al. Clinical characteristics and predictors of mortality in hospitalized HIV-infected Nigerians. J Infect Dev Ctries. 2011;5:377-82.
22. Kra O, Aba YT, Yao KH, Ouattara B, Abouo F, Tanon KA, et al. Clinical, biological, therapeutic and evolving profile of patients with HIV infection hospitalized at infectious and tropical diseases unit in Abidjan (Ivory Coast). Bull Soc Pathol Exot. 2013;106:37-42.
23. World Health Organization. WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children [Internet]. 2007 [cited 2007 Oct 25]. Available from: http://www.who.int/hiv/pub/guidelines/hivstaging/en/index.html
24. Anglaret X, Dakoury-Dogbo N, Bonard D, Toure S, Combe P, Ouassa T, et al. Causes and empirical treatment of fever in HIV-infected adult outpatients, Abidjan, Cote d'Ivoire. AIDS. 2002;16:909-18. (Pubitemid 34409015)
25. Anglaret X, Messou E, Oaussa T, Toure S, Dakoury-Dogbo N, Combe P, et al. Pattern of bacterial disease in a cohort of HIV-1 infected adults receiving cotrimoxazole prophylaxis, Abidjan, Côte d'Ivoire. AIDS. 2003;17:575-84. (Pubitemid 36293111)
26. Shelburne SA, Montes M, Hamill RJ. Immune reconstitution inflammatory syndrome: more answers, more questions. J Antimicrob Chemother. 2006;57:167-70. (Pubitemid 43160154)
27. MacLennan R. Items of patient information which may be collected by registries. In: IARC, editor. Cancer registration: principles and methods. Lyon: IARC Scientific; 1991. p. 43-63.
28. The Uppsala Monitoring Centre. The use of the WHO-UMC system for standardised case causality assessment [Internet]. 2012 [cited 2012 Oct 15]. Available from: http://who-umc.org/Graphics/26649.pdf
29. World Health Organization. International classification of diseases. 10th Rev ed. Geneva: World Health Organization; 1993.
30. Smith de Cherif TK, Schoeman JH, Cleary S, Meintjes G, Rebe K, Maartens G. Early severe morbidity and resource utilization in South African adults on antiretroviral therapy. BMC Infect Dis. 2009;9:205.
31. Iwuji C, Mayanja B, Weiss H, Atuhumuza E, Hughes P, Maher D, et al. Morbidity in HIV-1-infected individuals before and after the introduction of antiretroviral therapy: a longitudinal study of a population-based cohort in Uganda. HIV Med. 2011;12:553-61.
32. The IeDEA, ART Cohort Collaborations. Immunodeficiency at the start of combination antiretroviral therapy in low-, middle-, and high-income countries. J Acquir Immune Defic Syndr. 2014;65:e8-16.
33. Fortes Deguenonvo L, Manga NM, Diop SA, Dia Badiane NM, Seydi M, Ndour CT, et al. Current profile of HIV-infected patients hospitalized in Dakar (Senegal) [French]. Bull Soc Pathol Exot. 2011;104:366-70.
34. Oliveira MT, Latorre Mdo R, Greco DB. The impact of late diagnosis on the survival of patients following their first AIDS-related hospitalization in Belo Horizonte, Brazil. AIDS Care. 2012;24:635-41.
35. Lawn SD, Little F, Bekker LG, Kaplan R, Campbel E, Orrell C, et al. Changing mortality risk associated with CD4 cell response to antiretroviral therapy in South Africa. AIDS. 2009;23:335-42.
36. Cox JA, Lukande RL, Lucas S, Nelson AM, Van Marck E, Colebunders R. Autopsy causes of death in HIV-positive individuals in sub-Saharan Africa and correlation with clinical diagnoses. AIDS Rev. 2010;12:183-94.
37. Crump JA, Ramadhani HO, Morrissey AB, Saganda W, Mwako MS, Yang LY, et al. Invasive bacterial and fungal infections among hospitalized HIV-infected and HIV-uninfected adults and adolescents in northern Tanzania. Clin Infect Dis. 2011;52:341-8.
38. Desalu OO, Oluwafemi JA, Ojo O. Respiratory diseases morbidity and mortality among adults attending a tertiary hospital in Nigeria. J Bras Pneumol. 2009;35:745-52.
39. Anglaret X, Minga A, Gabillard D, Ouassa T, Messou E, Morris B, et al. AIDS and non-AIDS morbidity and mortality across the spectrum of CD4 cell counts in HIV-infected adults before starting antiretroviral therapy in Cote d'Ivoire. Clin Infect Dis. 2012;54:714-23.
40. Martinson NA, Karstaedt A, Venter WD, Omar T, King P, Mbengo T, et al. Causes of death in hospitalized adults with a premortem diagnosis of tuberculosis: an autopsy study. AIDS. 2007;21:2043-50. (Pubitemid 47462153)
41. Kouanda S, Meda IB, Nikiema L, Tiendrebeogo S, Doulougou B, Kabore I, et al. Determinants and causes of mortality in HIV-infected patients receiving antiretroviral therapy in Burkina Faso: a five-year retrospective cohort study. AIDS Care. 2012;24:478-90.
42. Cohen T, Murray M, Wallengren K, Alvarez GG, Samuel EY, Wilson D. The prevalence and drug sensitivity of tuberculosis among patients dying in hospital in KwaZulu-Natal, South Africa: a postmortem study. PLoS Med. 2012;7:e1000296.
43. Lawn SD, Harries AD, Meintjes G, Getahun H, Havlir DV, Wood R. Reducing deaths from tuberculosis in antiretroviral treatment programmes in sub-Saharan Africa. AIDS. 2012;26:2121-33.
44. Kambugu A, Meya DB, Rhein J, O'Brien M, Janoff EN, Ronald AR, et al. Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy. Clin Infect Dis. 2008;46:1694-701. (Pubitemid 351706766)
45. Jarvis JN, Meintjes G, Harrison TS. Outcomes of cryptococcal meningitis in antiretroviral naive and experienced patients in South Africa. J Infect. 2010;60:496-8.
46. Aoussi EF, Ehui E, Dembele JP, Kolia-Diafouka P, Elloh NF, Ouattara SI, et al. Cryptoccocal meningitis and HIV in the era of HAART in Cote d'Ivoire. Med Mal Infect. 2012;42:349-54.
47. World Health Organization. Rapid advice: diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents and children [Internet]. 2011. [cited 2014 Feb 5]. Available from: http://whqlibdoc.who.int/publications/2011/9789241502979-eng.pdf
48. Jarvis JN, Percival A, Bauman S, Pelfrey J, Meintjes G, Williams GN, et al. Evaluation of a novel point-of-care cryptococcal antigen test on serum, plasma, and urine from patients with HIV-associated cryptococcal meningitis. Clin Infect Dis. 2011;53:1019-23.
49. Marshall CS, Curtis AJ, Spelman T, O'Brien DP, Greig J, Shanks L, et al. Impact of HIV-associated conditions on mortality in people commencing anti-retroviral therapy in resource limited settings. PLoS One. 2013;8:e68445.
50. Whitworth J, Morgan D, Quigley M, Smith A, Mayanja B, Eotu H, et al. Effect of HIV-1 and increasing immunosuppression on malaria parasitaemia and clinical episodes in adults in rural Uganda: a cohort study. Lancet. 2000;356:1051-6.
51. Srikanth BA, Babu SC, Yadav HN, Jain SK. Incidence of adverse drug reactions in human immune deficiency virus-positive patients using highly active antiretroviral therapy. J Adv Pharm Technol Res. 2012;3:62-7.
52. Buchacz K, Baker RK, Moorman AC, Richardson JT, Wood KC, Holmberg SD, et al. Rates of hospitalizations and associated diagnoses in a large multisite cohort of HIV patients in the United States, 1994-2005. AIDS. 2008;22:1345-54.
53. Berry SA, Fleishman JA, Moore RD, Gebo KA. Trends in reasons for hospitalization in a multisite United States cohort of persons living with HIV, 2001-2008. J Acquir Immune Defic Syndr. 2012;59:368-75.
54. Lewden C, Bouteloup V, De Wit S, Sabin C, Mocroft A, Wasmuth JC, et al. All-cause mortality in treated HIV-infected adults with CD4 > =500/mm3 compared with the general population: evidence from a large European observational cohort collaboration. Int J Epidemiol. 2012;41:433-5.